Contract analysis

I. INTRODUCTORY STATEMENT AND IDENTIFICATION 1.1 Taxpayer Identification The taxpayer filing this Formal Protest is Penterra Pharmaceuticals Corp. ("PPC" or the "Company"), a corporation organized and existing under the laws of the State of Delaware, with its principal place of business located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC's Employer Identification Number ("EIN") is 22-374

II. STATEMENT OF FACTS 2.1 Corporate Overview Penterra Pharmaceuticals Corp. is a specialty pharmaceutical and biotechnology company engaged in the research, development, manufacture, and commercialization of pharmaceutical products. PPC's therapeutic areas of focus are oncology, immunology, and rare-disease therapeutics. The Company has been at the forefront of biologic drug development in these fields for over two

III. SUMMARY OF IRS PROPOSED ADJUSTMENTS 3.1 CSA Cost-Sharing Ratio Adjustments ($235,010,000) The IRS proposes to increase PBI's cost-sharing percentage under the CSA by approximately 8 to 12 percentage points for each of the Tax Years at Issue. The IRS asserts that PPC's projections of reasonably anticipated benefits used to determine the cost-sharing ratios understated the value of PPC's U.S.-based contributions t

IV. LAW AND ARGUMENT — CSA COST-SHARING RATIO 4.1 Legal Framework

Section 482 of the Internal Revenue Code grants the Secretary of the Treasury the authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among organizations, trades, or businesses owned or controlled by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income o

V. LAW AND ARGUMENT — LEGACY IP ROYALTY RATE 5.1 Legal Framework Treasury Regulation § 1.482-4 provides the methods for determining the arm's-length amount charged in a controlled transaction involving the transfer or use of intangible property. The specified methods include the comparable uncontrolled transaction ("CUT") method, the comparable profits method, and the profit split method, among others. The CUT method

VI. LAW AND ARGUMENT — PBI ECONOMIC SUBSTANCE AND DEMPE FUNCTIONS 6.1 Legal Framework The economic substance doctrine is a judicially developed principle that, in the transfer pricing context, requires that entities claiming income from or bearing costs related to intangible property have genuine substance commensurate with their claimed economic role. While IRC § 7701(o) codified the economic substance doctrine for